

02-31000-02

Original Effective Date: 04/15/18

Reviewed: 10/23/25

Revised: 11/15/25

## Subject: Balloon Dilation of the Eustachian Tube

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

<a href="#">Position Statement</a>	<a href="#">Billing/Coding</a>	<a href="#">Reimbursement</a>	<a href="#">Program Exceptions</a>	<a href="#">Definitions</a>	<a href="#">Related Guidelines</a>
<a href="#">Other</a>	<a href="#">References</a>	<a href="#">Updates</a>			

### DESCRIPTION:

Eustachian tube dysfunction (ETD) occurs when the functional valve of the eustachian tube fails to open and/or close properly. This failure is frequently due to inflammation and can cause symptoms such as muffled hearing, ear fullness, tinnitus, and vertigo. Chronic obstructive eustachian dysfunction can lead to hearing loss, otitis media, tympanic membrane perforation, and cholesteatomas.

Balloon dilation of the eustachian tube (BDET) is a tuboplasty procedure intended to improve the patency of the cartilaginous eustachian tube to cause local dilation. During the procedure, a saline-filled balloon catheter is introduced into the eustachian tube through the nose using a minimally invasive transnasal endoscopic method. Pressure is maintained for 2 minutes or less, after which the balloon is emptied and removed. The procedure is usually performed under general anesthesia.

**Summary and Analysis of Evidence:** Patients who have chronic obstructive ETD despite medical management who receive BDET, the evidence includes randomized controlled trials (RCTs), prospective observational studies, case series, and systematic reviews of these studies. Two 6-week RCTs found more improvement with balloon dilation plus medical management than medical management alone on patient-reported symptoms, ability to perform a Valsalva maneuver, proportion of patients with normalized tympanograms, and otoscopy findings. Durability of these effects was demonstrated at 52 weeks in the uncontrolled extension phase of both RCTs. No serious device- or procedure-related adverse events were reported through 52 weeks of followup. Multiple observational studies and case series have reported that patients experienced improvement when comparing symptoms before and after balloon dilation. Krogshede, et al (2022) concluded, "The procedure is feasible and no complications were reported. The study indicates that balloon dilation of the Eustachian tube may be a beneficial treatment in a selected group of adult patients with mild chronic Eustachian tube dysfunction". The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

## POSITION STATEMENT:

Balloon dilation of the eustachian tube with a U.S. Food and Drug Administration (FDA) approved device for treatment of chronic obstructive eustachian tube dysfunction **meets the definition of medical necessity** when **ALL** of the following are met:

1. Adults (age 18 years and older) with symptoms of obstructive eustachian tube dysfunction (aural fullness, aural pressure, otalgia, and/or hearing loss) lasting 3 months or longer in one or both ears that significantly affects quality of life or functional health status.
  - Aural fullness and pressure must be present;
2. The member has undergone a comprehensive diagnostic assessment; including patient-reported questionnaires, history and physical exam, tympanometry if the tympanic membrane is intact, nasal endoscopy, and comprehensive audiometry, with the following findings:
  - Abnormal tympanogram (Type B or C)
  - Abnormal tympanic membrane (retracted membrane, effusion, perforation, or any other abnormality identified on exam);
3. Failure to respond to appropriate medical management of potential co-occurring conditions, if any, such as allergic rhinitis, rhinosinusitis, and laryngopharyngeal reflux, including 4-6 weeks of a nasal steroid spray, if indicated;
4. Other causes of aural fullness such as temporomandibular joint disorders, extrinsic obstruction of the eustachian tube, superior semicircular canal dehiscence, and endolymphatic hydrops have been ruled out;
5. If the member had a history of tympanostomy tube placement, symptoms of obstructive eustachian tube dysfunction should have improved while tubes were patent;
6. The member does not have patulous eustachian tube dysfunction or another contraindication to the procedure\*;
7. The member's eustachian tube dysfunction has been shown to be reversible (demonstrated by several means such as the member states they are able to relieve the pressure by performing a Valsalva maneuver to "pop" their ears);
8. Symptoms are continuous rather than episodic (e.g., symptoms occur only in response to barochallenge such as pressure changes while flying); **AND**
9. The member has not had a previous balloon dilation of the eustachian tube procedure.

Balloon dilation of the eustachian tube is considered **experimental or investigational** if the above criteria are not met.

\*The following members should not be considered for balloon dilation of the eustachian tube:

- Members with patulous eustachian tube dysfunction (a diagnosis is suggested by symptoms of autophony of voice, audible respirations, pulsatile tinnitus, and/or aural fullness);
- Members with extrinsic reversible or irreversible causes of eustachian tube dysfunction including but not limited to:

- craniofacial syndromes, including cleft palate spectrum
  - neoplasms causing extrinsic obstruction of the eustachian tube
  - history of radiation therapy to the nasopharynx
  - enlarged adenoid pads
  - nasopharyngeal mass
  - neuromuscular disorders that lead to hypotonia/ineffective eustachian tube dynamic opening
  - systemic mucosal or autoimmune inflammatory disease affecting the mucosa of the nasopharynx and eustachian tube (e.g. Samter’s triad, Wegener’s disease, mucosal pemphigus) that is ongoing/active (i.e. not in remission)
- Members with aural fullness but normal exam and tympanogram
  - Members with chronic and severe atelectatic ears.

## BILLING/CODING INFORMATION:

### CPT Coding:

69705	Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); unilateral
69706	Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); bilateral

Unlisted CPT code 69799 may also be used to report balloon dilation of the eustachian tube.

### ICD-10 Diagnosis Codes That Support Medical Necessity:

H65.00 – H65.93	Nonsuppurative otitis media
H66.001 – H66.93	Suppurative and unspecified otitis media
H67.1 – H67.9	Otitis media in diseases classified elsewhere
H68.001 – H68.029	Eustachian salpingitis
H69.80 – H69.83	Other specified disorders of Eustachian tube
H69.90 – H69.93	Unspecified Eustachian tube disorder
H71.00 – H71.93	Cholesteatoma of middle ear
H72.00 – H72.93	Perforation of tympanic membrane
H81.311 – H81.399	Other peripheral vertigo
H81.4	Vertigo of central origin
H90.0 – H90.A32	Conductive and sensorineural hearing loss
H91.01 – H91.93	Other and unspecified hearing loss
J30.0 – J30.9	Vasomotor and allergic rhinitis
J31.0 – J31.2	Chronic rhinitis, nasopharyngitis and pharyngitis
J32.0 – J32.9	Chronic sinusitis

## REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

## PROGRAM EXCEPTIONS:

**Federal Employee Program (FEP):** Follow FEP guidelines.

**State Account Organization (SAO):** Follow SAO guidelines.

**Medicare Advantage products:** No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) was found at the time of the last guideline reviewed date.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

## DEFINITIONS:

No guideline specific definitions apply.

## RELATED GUIDELINES:

None applicable.

## OTHER:

None applicable.

## REFERENCES:

1. Aboueisha MA, Attia AS, et al. Efficacy and safety of balloon dilation of eustachian tube in children: Systematic review and meta-analysis. *Int J Pediatr Otorhinolaryngol*. 2022 Mar;154:111048. PMID: 35085875.
2. Acclarent, Inc. Acclarent Balloon Dilation of the Eustachian Tube for the Treatment of Persistent Eustachian Tube Dysfunction Evidence Compendium, 2021.
3. Ahluwalia J, Babu S, et al. Outcomes of Concurrent Balloon Eustachian Tuboplasty and Tympanostomy Tube Placement in Children. *Laryngoscope*. 2024 Nov;134(11):4799-4802. doi: 10.1002/lary.31572. Epub 2024 Jun 14. PMID: 38872456.
4. Ahluwalia J, Babu S, et al. Safety Outcomes of Balloon Dilation Eustachian Tuboplasty in Pediatric Patients: A Follow-Up Study. *Otol Neurotol*. 2025 Jan 1;46(1):67-71. doi: 10.1097/MAO.0000000000004347. Epub 2024 Nov 6. PMID: 39511742.
5. American Academy of Otolaryngology Head and Neck Surgery. Eustachian Tube Balloon Dilation in the Pediatric Population, July 2025; accessed at: [entnet.org](http://entnet.org).
6. Anand V, Poe D, et al. Balloon Dilation of the Eustachian Tube: 12-Month Follow-up of the Randomized Controlled Trial Treatment Group. *Otolaryngol Head Neck Surg*. Apr 2019; 160(4): 687-694. PMID: 30620688.
7. Blue Cross Blue Shield Association Evidence Positioning System®. 7.01.158 Balloon Dilation of the Eustachian Tube, 10/24.
8. Bowles PF, Agrawal S, Salam MA, Balloon tuboplasty in patients with Eustachian tube dysfunction: a prospective study in 39 patients (55 ears). *Clin Otolaryngol*. 2017 Oct;42(5):1057-1060.

9. Cutler JL, Meyer TA, et al. Long-term Outcomes of Balloon Dilation for Persistent Eustachian Tube Dysfunction. *Otol Neurotol*. Dec 2019; 40(10): 1322-1325. PMID: 31385858.
10. Formanek M, Formankova D, et al. Effect of Balloon Eustachian Tuboplasty in Adults That Only Have Symptoms of Chronic Eustachian Tube Dysfunction, With a 1-Year Follow-Up: Prospective Clinical Trial. *Ear Nose Throat J*. 2020 Dec 10;145561320980199. PMID:33297745.
11. Froehlich MH, Le PT, et al. Eustachian Tube Balloon Dilation: A Systematic Review and Meta-analysis of Treatment Outcomes. *Otolaryngol Head Neck Surg*. Jun 02 2020: 194599820924322. PMID: 32482125.
12. Gurberg J, Dean M, et al. Long-term efficacy of balloon dilation of the pediatric Eustachian tube: A six-year matched cohort study. *Am J Otolaryngol*. 2024 May-Jun;45(3):104208. doi: 10.1016/j.amjoto.2023.104208. Epub 2023 Dec 22. PMID: 38154198.
13. Huisman JML, Verdam FJ, et al. Treatment of Eustachian tube dysfunction with balloon dilation: A systematic review. *Laryngoscope*. 2018 Jan;128(1):237-247. Doi: 10.1002/lary.26800. Epub 2017 Aug 11. PMID: 28799657.
14. Keschner D, Garg R, et al. Repeat Eustachian Tube Balloon Dilation Outcomes in Adults With Chronic Eustachian Tube Dysfunction. *Otolaryngol Head Neck Surg*. 2021 Aug 17;1945998211037975. PMID: 34399641.
15. Krogshede SK, Kirchmann M, et al. Balloon Dilation of the Eustachian Tube: A Randomized Controlled Trial with 6 Months Follow-Up. *J Int Adv Otol*. 2022 Nov;18(6):501-506.
16. Liu YC, Dean M, et al. Balloon Dilation of the Eustachian Tube (BDET)-A Pooled Analysis in Pediatric Patients. *Laryngoscope*. 2025 Jun 27. doi: 10.1002/lary.32356. Online ahead of print. PMID: 40574604.
17. Merrill T, Patel V, et al. Is there a role for Eustachian tube balloon dilation in pediatric patients with refractory Eustachian tube dysfunction? *Am J Otolaryngol*. 2023 Jul-Aug;44(4):103896. doi: 10.1016/j.amjoto.2023.103896. PMID: 37068320.
18. Meyer TA, O'Malley EM, Schlosser RJ, et al. A Randomized Controlled Trial of Balloon Dilation as a Treatment for Persistent Eustachian Tube Dysfunction With 1-Year Follow-Up. *Otol Neurotol*. Aug 2018;39(7):894-902.
19. National Institute for Health and Care Excellence (NICE). Balloon dilation for chronic eustachian tube dysfunction. *Interventional procedures guidance [IPG665]*. December 2019; accessed at nice.org.uk.
20. Pelton S, Marom T. Otitis media with effusion (serous otitis media) in children: Management. In *UpToDate*, Kaplan SL, Isaacson GC, Torchia MM (eds). *UpToDate*, Waltham, MA; accessed at uptodate.com.
21. Poe D. Eustachian tube dysfunction, 2023. In *UpToDate*, Deschler DG, Kunins L (eds), *UpToDate*, Waltham, MA; accessed October 2024 at uptodate.com.
22. Poe D, Anand V, et al. Balloon dilation of the eustachian tube for dilatory dysfunction: A randomized controlled trial. *Laryngoscope*. 2018 May;128(5):1200-1206. Doi: 10.1002/lary.26827. Epub 2017 Sep 20. PMID: 28940574.
23. Saniasiaya J, Kulasegarah J, Narayanan P. Outcome of Eustachian Tube Balloon Dilation in Children: A Systematic Review. *Ann Otol Rhinol Laryngol*. 2021 Aug 22;34894211041340. PMID: 34423675.
24. Satmis MC, van der Torn M. Balloon dilatation of the Eustachian tube in adult patients with chronic dilatory tube dysfunction: a retrospective cohort study. *Eur Arch Otorhinolaryngol*. Feb 2018;275(2):395-400. PMID 29285624.
25. Schmitt D, Akkari M, et al. Medium-term assessment of eustachian tube function after balloon dilation. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2018 Apr;135(2):105-110. Doi: 10.1016/j.anorl.2017.09.008. Epub 2017 Dec 28. PMID: 29289487.

26. Singh T, Taneja V, et al. Balloon Eustachian tuboplasty treatment of longstanding Eustachian tube Dysfunction. J Laryngol Otol. 2017 Jul;131(7):614-619. Doi: 10.1017/S0022215117000974. Epub 2017 May 15. PMID: 28502258.
27. Teschner M, Evidence and evidence gaps in the treatment of Eustachian tube dysfunction and otitis media. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2016 Dec 15;15:Doc05.
28. Tucci DL, McCoul ED, et al. Clinical Consensus Statement: Balloon Dilatation of the Eustachian Tube. Otolaryngol Head Neck Surg. Jul 2019; 161(1):6-17.
29. U.S. Food & Drug Administration (FDA); accessed at fda.gov.
30. Wang TC, Lin CD, et al. Comparison of Balloon Dilatation and Laser Eustachian Tuboplasty in Patients with Eustachian Tube Dysfunction: A meta-analysis. Otolaryngol Head Neck Surg. 2018 Apr;158(4):617-626. Doi: 10.1177/0194599817753609. Epub 2018 Mar 20. PMID: 29557245.

### COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 10/23/25.

### GUIDELINE UPDATE INFORMATION:

04/15/18	New Medical Coverage Guideline.
04/15/19	Annual review; Position statement maintained and references updated.
11/15/20	Review; Position statements, coding, and references updated.
01/01/21	Annual CPT/HCPCS update. Codes 69705 and 69706 added; code C9745 deleted.
11/15/21	Review; Position statements updated; references updated.
12/15/22	Review: Position statements maintained and references updated.
05/23/23	Update to Program Exceptions section.
11/15/23	Review: Position statements maintained; references updated.
11/15/24	Review: Position statements maintained; description and references updated.
11/15/25	Annual review: <i>FDA approved device</i> added to coverage statement; references updated.